Thoracic duct lymphocyte depletion, a technique that selectively suppresses cellular immune defenses, was performed in a patient with myasthenia gravis. The patient demonstrated a 70% reduction in anticholinesterase medication requirement. These data lend further support to the apparent relationship between myasthenia gravis, the thymus, and cell-mediated immunity and implicate the lymphocyte, or a substance bound to it, as a contributing factor in myasthenia gravis.
Tindall SC, Peters BH, Caverley JR, Sarles HE, Fish JC. Thoracic Duct Lymphocyte Depletion in Myasthenia Gravis. Arch Neurol. 1973;29(3):202–203. doi:10.1001/archneur.1973.00490270084016
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.